Mizuho sees Pfizer patent trial as the single largest catalyst for BridgeBio (BBIO) stock this year
Mizuho analyst Salim Syed reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst commented, "The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)